References
Original article
Wainberg, Z. A. et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00603-9 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Bemarituzumab enters the FIGHT. Nat Rev Clin Oncol 20, 2 (2023). https://doi.org/10.1038/s41571-022-00705-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00705-2
- Springer Nature Limited